Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04776980 | Multimodality MRI and Liquid Biopsy in GBM | withdrawn | Early Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04267900 | 99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer | completed | Early Phase 1 | 34 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05539768 |
| Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor |
| not yet recruiting |
| Early Phase 1 |
| 8 |
| The Affiliated Hospital of Qingdao UniversityOTHER |
| 0 |
| Sep 14, 2022 |
| clinicaltrials |
| NCT00962845 | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | completed | Early Phase 1 | 20 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT03020017 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | completed | Early Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05515185 | B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors | unknown | Early Phase 1 | 30 | The First People's Hospital of LianyungangOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | withdrawn | Early Phase 1 | 0 | Flame BiosciencesINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT04974281 | PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC | unknown | Early Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05505812 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer | not yet recruiting | Early Phase 1 | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04102618 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer(AWARE-1) | terminated | Early Phase 1 | 26 | Oncolytics BiotechINDUSTRY | 1 | Aug 15, 2022 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT00978562 | DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors | completed | Early Phase 1 | 14 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT04019834 | Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy(RELIEF) | completed | Early Phase 1 | 21 | University of Alabama at BirminghamOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05013372 | CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | unknown | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04065555 | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | completed | Early Phase 1 | 12 | Presage BiosciencesINDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05480501 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | terminated | Early Phase 1 | 6 | Yale UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01781741 | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Early Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02885272 | FDG PET Imaging in Diagnosing Patients With Glioblastoma | completed | Early Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03982407 | 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma | completed | Early Phase 1 | 5 | Ajit H. Goenka, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT04996602 | Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05459441 | Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases | unknown | Early Phase 1 | 30 | Shanghai Pudong HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04288336 | Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT04891718 | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | withdrawn | Early Phase 1 | 0 | Presage BiosciencesINDUSTRY | 1 | Jul 8, 2022 | clinicaltrials |
| NCT02626130 | Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | completed | Early Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05438797 | The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer | unknown | Early Phase 1 | 3 | Sizhen WangOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 100 | Zhejiang UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT02046694 | A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL | completed | Early Phase 1 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity | withdrawn | Early Phase 1 | 0 | University Hospitals Cleveland Medical CenterOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04630210 | Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity(AteBrO) | withdrawn | Early Phase 1 | 0 | Universitaire Ziekenhuizen KU LeuvenOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy | terminated | Early Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Jun 14, 2022 | clinicaltrials |
| NCT04936997 | Immune Response to the COVID-19 Vaccine | completed | Early Phase 1 | 20 | University of ArizonaOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT05382377 | NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT04803630 | Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05364177 | 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT04266392 | Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand | completed | Early Phase 1 | 20 | Stony Brook UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05361083 | First-in-human Evaluation of [18F]CETO | completed | Early Phase 1 | 20 | Uppsala UniversityOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT03891654 | Dynamic Contrast Enhanced Computed Tomography to Assess Radiation Therapy in Liver Cancer Patients | completed | Early Phase 1 | 3 | University of Colorado, DenverOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT03825718 | A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | completed | Early Phase 1 | 29 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05141253 | Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | recruiting | Early Phase 1 | 24 | Tongji HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04721756 | Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging | unknown | Early Phase 1 | 30 | Avid RadiopharmaceuticalsINDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival(RESECT) | terminated | Early Phase 1 | 2 | University Health Network, TorontoOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03028519 | Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer | completed | Early Phase 1 | 81 | University of OklahomaOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | terminated | Early Phase 1 | 1 | Presage BiosciencesINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Sep 16, 2022source: clinicaltrials